Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Newborn AcquisitionPetra AcquisitionLIV Capital Acquisition5:01 AcquisitionLifeSci Acquisition II
SymbolNASDAQ:NBACNASDAQ:PAICNASDAQ:LIVKNASDAQ:FVAMNASDAQ:LSAQ
Price Information
Current Price$15.52$10.04$9.98$10.19$10.07
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score1.20.00.20.00.0
Analysis Score0.00.00.00.00.0
Community Score5.00.00.00.00.0
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.80.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$115.78 million$91.34 million$101.22 million$87.85 million$100.81 million
BetaN/AN/AN/AN/AN/A
Average Volume351,42625,04638,52132,72233,183
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/AN/AN/AN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E Ratio∞∞∞∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio6.98%N/A2.53%0.47%N/A
Quick Ratio6.98%N/A2.53%0.47%N/A
Ownership Information
Institutional Ownership Percentage48.23%N/A50.95%N/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/AN/AN/AN/AN/A
Shares Outstanding7.46 million9.10 million10.13 million8.62 million10.01 million
Next Earnings Date5/13/2021 (Estimated)N/AN/AN/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc. - MarketWatchOncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc. - MarketWatch
marketwatch.com - April 21 at 9:44 AM
Lectra: Lectra shareholders’ vote on Gerber Technology acquisition project postponedLectra: Lectra shareholders’ vote on Gerber Technology acquisition project postponed
au.finance.yahoo.com - April 20 at 11:47 PM
Nicola Wealth Real Estate finds value in Scarborough and further expands their Industrial FootprintNicola Wealth Real Estate finds value in Scarborough and further expands their Industrial Footprint
sg.finance.yahoo.com - April 15 at 7:34 AM
LifeSci Acquisition II Corp. (NASDAQ:LSAQ) Short Interest Up 675.0% in MarchLifeSci Acquisition II Corp. (NASDAQ:LSAQ) Short Interest Up 675.0% in March
americanbankingnews.com - April 13 at 6:16 AM
The Best 5G Play in Canada Just Got a Lot BiggerThe Best 5G Play in Canada Just Got a Lot Bigger
ca.finance.yahoo.com - March 27 at 8:53 AM
LifeSci Acquisition II Corp. (NASDAQ:LSAQ) Short Interest Down 68.8% in MarchLifeSci Acquisition II Corp. (NASDAQ:LSAQ) Short Interest Down 68.8% in March
americanbankingnews.com - March 27 at 6:50 AM
Incubeta Acquires Ecommerce Agency GroundswellIncubeta Acquires Ecommerce Agency Groundswell
au.finance.yahoo.com - March 18 at 8:49 AM
Big Cypress Acquisition Corp. Announces Pricing of $100 Million Initial Public OfferingBig Cypress Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
wallstreet-online.de - January 13 at 8:53 AM
KludeIn I Acquisition Corp. Announces Pricing of $150,000,000 Initial Public OfferingKludeIn I Acquisition Corp. Announces Pricing of $150,000,000 Initial Public Offering
wallstreet-online.de - January 8 at 8:47 PM
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public OfferingLifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering
finance.yahoo.com - December 14 at 8:29 AM
DateCompanyBrokerageAction
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.